{"brief_title": "Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI", "brief_summary": "The purpose of the study is evaluate the efficacy, safety, and pharmacokinetics of weekly intravenous infusions of 1 mg/kg recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) in patients diagnosed with Mucopolysaccharidosis VI (MPS VI)", "condition": "Mucopolysaccharidosis VI", "intervention_type": "Drug", "intervention_name": "N-acetylgalactosamine 4-sulfatase", "criteria": "Inclusion Criteria: - Patient consent - Patient must be five years of age or older - Patient must have documented biochemical or genetic proof of MPS VI - Patient must walk at least 1 meter, but less than 250 meters, in the first 6 minutes of the baseline 12-minute walk test - If female of childbearing potential, patient must have a negative pregnancy test Exclusion Criteria: - Patient is under consideration for or has undergone a successful bone marrow transplant (BMT). - Pregnant or lactating patient - Patient has received an investigational drug within 30 days prior to study enrollment - Patient has been previously treated with rhASB - Patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly confound study results or decrease study compliance - Patient has a known hypersensitivity to rhASB or to components of the study drug - History of cancer (except low grade and fully resolved skin malignancy)", "gender": "All", "minimum_age": "5 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00048711.xml"}